Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
GlobeNewswire
· Continuous Kesimpta^® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years)..
